Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).
Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.
Diabetic Proliferative Retinopathy
Vascular Vein Oclussion
Drug: Intravitreal Bevacizumab
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label